Advertisement
Advertisement
U.S. markets close in 3 hours 58 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Progenity, Inc. (PROG)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.3305-0.0995 (-6.96%)
As of 12:02PM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
MACD

MACD

Previous Close1.4300
Open1.4400
Bid1.3400 x 1000
Ask1.3500 x 29200
Day's Range1.3100 - 1.4600
52 Week Range0.6570 - 7.4400
Volume3,284,468
Avg. Volume36,524,167
Market Cap217.869M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.4440
Earnings DateMar 16, 2022 - Mar 21, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for PROG

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Progenity, Inc.
    Analyst Report: Agilent Technologies, Inc.Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2020 sales), cross lab (36% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Just over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (33%) and China (20%) representing the largest country concentrations.
    Rating
    Fair Value
    Economic Moat
    10 months agoMorningstar
View more
  • GlobeNewswire

    Progenity Strengthens Intellectual Property for Single-Molecule Detection Technology with Additional Patent

    SAN DIEGO, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced the award of another new patent related to its single-molecule detection assay platform under development. The USPTO has issued U.S. Patent No. 11,230,731 entitled, “Methods, Systems, and Compositions for Counting Nucleic Acid Molecules.” The issued claims are directed to detecting a labeled target molecule on a solid support. “We have added another important patent t

  • GlobeNewswire

    Progenity Announces Oral Presentation on Treatment of Gastrointestinal Disorders at 34th Belgian Week of Gastroenterology

    Dr. Bram Verstockt to present patient data establishing correlation between drug levels in colon and clinical outcomesSAN DIEGO, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced that patient data on indicators of efficacy in the treatment of gastrointestinal disorders has been accepted for oral presentation during the 34th edition of the Belgian Week of

  • InvestorPlace

    Progenity Stock’s Hype Cycle Is Over, It Needs Results

    Progenity (NASDAQ:PROG) stock is a small biotech company that drew a lot of investor excitement last year, largely thanks to short squeezes. Source: Mongkolchon Akesin / Shutterstock.com It took advantage of the interest to get out of the lab business, eventually laying off 110 people in Michigan. It sold the assets of its Avero Diagnostics unit in December. What’s left are 96 sets of patents, along with 220 patent applications, which it wants partners to help exploit.InvestorPlace - Stock Marke

Advertisement
Advertisement